EPIC Program Annual Data Tables 2007-2008: Table VII
| Therapeutic Class** | Number of Claims |
Percent of Claims |
EPIC Payments |
Number of Participants |
|---|---|---|---|---|
| Total*** | 4,848,241 | 45.44% | $187,936,484 | |
| BETA-ADRENERGIC BLOCKING AGENT | 891,814 | 8.36% | $13,559,376 | 153,894 |
| HMG-COA REDUCTASE INHIBITORS | 709,226 | 6.65% | $39,173,380 | 152,215 |
| ANGIOTENSIN-CONVERTING ENZYME | 525,546 | 4.93% | $9,371,819 | 96,939 |
| PROTON-PUMP INHIBITORS | 507,920 | 4.76% | $49,887,847 | 97,733 |
| ANTIDEPRESSANTS | 417,695 | 3.91% | $14,090,259 | 68,715 |
| DIHYDROPYRIDINES | 398,753 | 3.74% | $13,329,958 | 73,183 |
| ANGIOTENSIN II RECEPTOR ANTAGO | 393,768 | 3.69% | $20,438,189 | 77,058 |
| THYROID AGENTS | 353,103 | 3.31% | $2,612,597 | 60,608 |
| BONE RESORPTION INHIBITORS | 329,070 | 3.08% | $17,452,767 | 56,828 |
| OPIATE AGONISTS | 321,346 | 3.01% | $8,020,292 | 83,073 |
* Table VII provides the percent of adjudicated claims for the program year (October 1, 2007 through September 30, 2008) as they fall into particular categories of Therapeutic Class.
** American Hospital Formulary Service® (AHFS) Pharmacologic-Therapeutic Classification.
*** This report contains the top ten drug classes; additional drug classes comprise the remainder of claims up to 100.00%.
